Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis – – P...